Any current/future new fundraising through debt or equity?

No new long-term debt fundraising is planned; management expects long-term debt to be practically zero by FY '27, largely through warrant conversions in FY '26. Proceeds from warrant conversion in FY '26 will be used to repay approximately INR185 crores of long-term debt, aiding deleveraging. Short-term debt (~INR1,100 crores) will be used primarily as a balancing figure for working capital utilization; no significant repayment pressure expected. No immediate equity fundraising is mentioned; focus appears to be on utilizing existing resources and warrant proceeds. Capex needs for new projects

Any current/future capex/capital investment/strategic investment?

No additional capex required for servicing the first 1,000 tons of demand for the new AI product; this will be met with current capacities. Potential capex will be considered only upon ramp-up or securing a take-or-pay contract for higher volumes. Current assets can support production worth INR60-70 crores annually for Elementium orders; possible debottlenecking can increase this to INR100 crores without major capex. For scaling Elementium's full potential (approx. $70-$90 million revenue p.a.), significant capex will be necessary. INR670 crores of planned capex completed, with two manufacturi

Future growth expectations in sales/revenue/volumes?

Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards. Majority of LOIs worth approx. INR14,600 crores will commercialize over 4-10 years, contributing ~INR2,000 crores annual incremental revenue over 2-3 years. New product ramp-ups, especially in Pharma (20%-25% of revenue in FY '26) and Polymer/Performance Chemicals (expected to rise to 25%+ revenue in FY '26), plus recovery in agrochemicals expected to drive volume growth. Agrochemical demand is rebounding with volume-led growth; new high-value AI molecules contribute significantly with triple-digit dol

Future growth expectations in earnings/operating earnings/profits/EPS?

Company targets a return to historical growth rates of 25-30%+ from FY '26 onwards. Revenue growth driven by commercialization and ramp-up of LOIs, expected to mature over 2-4 years. Pharma and Polymer segments are key growth drivers, with Pharma expected to be 20-25% and Polymer 25%+ of revenue in FY '26. EBITDA margins are expected to remain consistent in the 26-28% range, supported by diversified product mix. Operating cash flow generation is strong (INR 140+ crores in the recent half), with expectations for improvement via working capital optimization. Long-term debt is planned to be reduc

Current/ Expected Orderbook/ Pending Orders?

Current order book stands at approximately INR 14,646 crores, spread over 4 to 10 years. Out of this, INR 3,100 crores worth of LOIs and contracts have already been commercialized. These commercialized orders contribute to over 20% of revenue in FY '25. Majority of the remaining LOIs and contracts are expected to be commercialized in FY '26. A significant LOI product in the agrochemical segment (an AI molecule) was signed in Q4 2022 and is currently ramping up, expected to contribute triple-digit million dollar revenue. The orderbook supports expected revenue ramp-ups, including around $70-90

IN US

Sale is live|00:00:00left today

Anupam Rasayan India LtdQ1 FY25Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,266P/E: 91.1Market Cap: ₹15.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards.
→Majority of LOIs worth approx. INR14,600 crores will commercialize over 4-10 years, contributing ~INR2,000 crores annual incremental revenue over 2-3 years.
→New product ramp-ups, especially in Pharma (20%-25% of revenue in FY '26) and Polymer/Performance Chemicals (expected to rise to 25%+ revenue in FY '26), plus recovery in agrochemicals expected to drive volume growth.
→Agrochemical demand is rebounding with volume-led growth; new high-value AI molecules contribute significantly with triple-digit dollar per kg pricing.
→Volume, rather than price, is expected to drive growth; pricing impact is minimal.
→LOI commercialization progressing: ~INR200 crores revenue already from 2022 LOIs; 2023 LOIs expected to commercialize by 2026.
→Current capacities support initial volumes; significant capex planned to meet higher-scale production needs by FY '27 and beyond.

Margin guidance

Category 3

→Company targets a return to historical growth rates of 25-30%+ from FY '26 onwards.
→Revenue growth driven by commercialization and ramp-up of LOIs, expected to mature over 2-4 years.
→Pharma and Polymer segments are key growth drivers, with Pharma expected to be 20-25% and Polymer 25%+ of revenue in FY '26.
→EBITDA margins are expected to remain consistent in the 26-28% range, supported by diversified product mix.
→Operating cash flow generation is strong (INR 140+ crores in the recent half), with expectations for improvement via working capital optimization.
→Long-term debt is planned to be reduced to near zero by FY '27 through warrant conversions.
→Working capital days target is around 150-180 days for incremental revenues, supporting cash flow efficiency.
→New high-value molecules, including AI and EV battery chemicals, offer significant revenue upside with triple-digit dollar/kg pricing.

3 more insights locked — sign up free to unlock

Fundraise plans

→No new long-term debt fundraising is planned; management expects long-term debt to be practically zero by FY '27, largely through warrant conversions in FY '26.
→Proceeds from warrant conversion in FY '26 will be used to repay approximately INR185 crores of long-term debt, aiding deleveraging.
→Short-term debt (~INR1,100 crores) will be used primarily as a balancing figure for working capital utilization; no significant repayment pressure expected.
→No immediate equity fundraising is mentioned; focus appears to be on utilizing existing resources and warrant proceeds.
→Capex needs for new projects (e.g., Elementium product) will be evaluated and communicated later; initial ramp-ups are planned within current capacities without extra capex.

Order book

Yes

→Current order book stands at approximately INR 14,646 crores, spread over 4 to 10 years.
→Out of this, INR 3,100 crores worth of LOIs and contracts have already been commercialized.
→These commercialized orders contribute to over 20% of revenue in FY '25.
→Majority of the remaining LOIs and contracts are expected to be commercialized in FY '26.
→A significant LOI product in the agrochemical segment (an AI molecule) was signed in Q4 2022 and is currently ramping up, expected to contribute triple-digit million dollar revenue.
→The orderbook supports expected revenue ramp-ups, including around $70-90 million from key products.
→Strong order book, new product launches, and enhanced capacity underpin confidence in returning to historical growth rates.

Capex plans

Yes

→No additional capex required for servicing the first 1,000 tons of demand for the new AI product; this will be met with current capacities.
→Potential capex will be considered only upon ramp-up or securing a take-or-pay contract for higher volumes.
→Current assets can support production worth INR60-70 crores annually for Elementium orders; possible debottlenecking can increase this to INR100 crores without major capex.
→For scaling Elementium's full potential (approx. $70-$90 million revenue p.a.), significant capex will be necessary.
→INR670 crores of planned capex completed, with two manufacturing facilities commercialized and one facility ready for commercialization imminently.
→Capex will focus on expanding production capacity to support next-phase growth and new molecule launches.
→No term debt expected by FY '27, as warrant conversions will largely repay it; short-term debt primarily balances working capital needs.
→Management will share detailed capex plans in future calls once finalized.

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan India Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Anupam Rasayan India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio